Bringing together outstanding experts from across the Yanzhao region and remaining committed to its founding mission for fourteen years. On August 21, 2026,the 14th Lu Daopei Hematology Forum officially opened at Hebei Yanda Ludaopei Hospital. Building on fourteen years of academic development, this year's conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases. It brought together leading experts and scholars in hematology from across China to explore advances in the field, serving as an important academic platform for promoting progress in the diagnosis and treatment of hematologic diseases in China. During the conference, Oncology Frontier – Hematology Frontier invited Dr. Chen Man of Ludaopei Hospital for an exclusive interview. She shared her professional insights on the clinical value of lymphocyte subset monitoring, its application in differentiating complications following hematopoietic stem cell transplantation (HSCT), and future directions in immune monitoring.

Bringing together leading experts and remaining committed to advancing the field, the 14th Lu Daopei Hematology Forum opened on August 21, 2026, at Hebei Yanda Ludaopei Hospital. After fourteen years of academic development, this year's conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases, bringing together experts and scholars from across China to explore advances in the field. During the conference, Oncology Frontier – Hematology Frontier invited Professor Robert Negrin, Director of the Division of Blood and Marrow Transplantation at Stanford University, for an in-depth interview. He shared his insights into milestone developments in regulatory T-cell (Treg) research, the clinical significance of the breakthrough achieved with Orca-T therapy, and future directions for expanding the Treg technology platform.

In the golden autumn season, colleagues from across the mountains and seas came together. The 2026 Cross-Strait Hematology Conference was held in Zhuhai, Guangdong, on August 21–22, bringing together hematology experts and scholars from the Chinese mainland, Taiwan, Hong Kong, and Macao to engage in in-depth discussions on advances in the field, clinical practice, and nursing innovation. During the conference, Professor Lanping Xu of Peking University People's Hospital, Chair of the Hematology Committee of the Cross-Strait Medical and Health Exchange Association and Conference Chair, spoke with the media about the conference agenda, complementary strengths in hematopoietic stem cell transplantation across the mainland and Taiwan, and the long-term value of the academic platform.

On August 21, 2026, the 14th Lu Daopei Hematology Forum officially opened at Hebei Yanda Lu Daopei Hospital. Over the past 14 years, the conference has built a strong academic foundation. This year's meeting focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases, bringing together experts and scholars from across China to discuss advances in the field. During the conference, Oncology Frontier – Hematology Frontier invited Professor Xian Zhang of Hebei Yanda Lu Daopei Hospital for an interview. He shared his insights into the evolving treatment landscape of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), the timing and clinical value of immunotherapy, and strategies for managing treatment-resistant and relapsed disease.